Panelists say drug price negotiation, Medicaid changes, prior authorization, and 340B reform strain community oncology.
|Articles|November 12, 2012
Not Enough Cancer Drugs, Too Many Price Controls
Advertisement
Cancer patients face daunting challenges, including side effects of treatment, impact on family life and work disruptions. They now face another problem: shortages of vital drugs.
Imagine an oncologist talking to his patient: Everything is going well with your treatment, he says, but one of the drugs you've been receiving is unavailable. There's a substitute—sort of. Your Medicare copayment for the drug we've been using is $9. Now it will cost you $520 each time the substitute is given.
Read the full story:
Source: The Wall Street Journal
Advertisement
Related to this article
The 2026 COA Payer Exchange and Innovation Summit began with a panel on AI and the ever-changing digital infrastructure in community oncology.
Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.
Experts tackled CAR T access, trial equity, and overtreatment in breast cancer at an AJMC Institute for Value-Based Medicine event in San Francisco.
The NPS index, ranging from –100 to +100, serves as a proxy for customers’ willingness to recommend products and services they themselves have used.
North Carolina experts discussed CLL, breast cancer, and myeloma treatments and how to expand access to complex cancer care beyond academic centers.
The IRA's Medicare out-of-pocket cap is easing costs for patients with cancer, but community oncology leaders warn price cuts are straining practices.
Biomarker testing, referrals, screening, treatment access, and clinical trial barriers were examined during this recent IVBM.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Cap Eases Patient Costs as Negotiation Squeezes Practices
2
Access and Innovation in North Carolina’s Research Triangle
3
An Odyssey of Symptoms, Setbacks, Treatments, and a Cure With CAR T-Cell Therapy
4
IRA, 340B, Medicaid: The Policy Pressures on Community Oncology
5